CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Payment Policy | Drugs and Biologicals

Governs reimbursement/payment review and claim edits for drugs and biologicals covered under members' medical benefits for Blue Cross & Blue Shield of Rhode Island; affects providers submitting medical-benefit drug claims.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyPayment Policy | Drugs and Biologicals

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateDec 7, 2017

Next Review DateN/A

Key ActionFile all medical-benefit drug claims with an administration code and National Drug Code (NDC).

SourceLink

NDC + admin codeclaim filing requirement

Lowest-cost comparablereimbursement approach

May vary by groupbenefits variability

Medical-benefit Drug Coverage Rules

Medical-benefit drug coverage rules

Coverage and reimbursement rules for drugs and biologics under the medical benefit.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyPayment Policy | Drugs and Biologicals

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateDec 7, 2017

Next Review DateN/A

Key ActionFile all medical-benefit drug claims with an administration code and National Drug Code (NDC).

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Benefits may vary between groups and contracts; refer to member-specific benefit documents for applicability.

Prescription drugs that can be self-administered and do not have an FDA recommendation for provider supervision are not covered as a medical benefit and may be covered under the pharmacy benefit.

All drugs must be filed with an administration code and National Drug Code (NDC).

Claims for medical-benefit drugs are screened for coding errors and dosages exceeding generally accepted limits; denials for medical necessity (e.g., diagnosis or unusual dosage) are subject to utilization review.

If no specific BCBSRI policy exists for an agent, BCBSRI will rely on manufacturer's prescribing information (FDA approved label), Elsevier Gold Standard Clinical Pharmacology, NCCN Drugs & Biologics Compendium, and Local Coverage Determinations.

For physician‑administered medications covered under the medical benefit, reimbursement may be based on the lowest cost drug among clinically comparable drugs within a therapeutic class; BCBSRI may limit coverage based on cost‑effectiveness among therapeutically similar agents.

These edits do not replace prior authorization when required; all claim submissions remain subject to BCBSRI prior authorization requirements.

Claim Filing and Coding Requirements

claim filingmixed

NDC + administration code

Claims must be filed with an administration code and National Drug Code (NDC).

Prior Authorization and Provider Guidance

Prior Authorization

Prior authorization required for claims

All claim submissions remain subject to Blue Cross & Blue Shield of Rhode Island prior authorization requirements. Prior authorization section of this policy is listed as Not applicable.

Definitions and Notes

Newly FDA approved Drugs — Notes and reimbursement approach

DefinitionNewly FDA approved drugs – drugs and biologicals recently approved by the U.S. Food and Drug Administration that are subject to BCBSRI review under the medical benefit.

Reimbursement approachFor physician‑administered medications covered under the medical benefit, reimbursement may be based on the lowest cost drug among clinically comparable drugs within a therapeutic class; BCBSRI may limit coverage based on cost‑effectiveness within therapeutically similar agents.

Review processWhen no specific BCBSRI policy exists for an agent, BCBSRI will rely on manufacturer prescribing information (FDA label), Elsevier Gold Standard Clinical Pharmacology, NCCN Drugs & Biologics Compendium, and Local Coverage Determinations.

Claims handlingClaims for newly approved drugs are subject to the same claim edits used to screen coding errors and dosages that exceed generally accepted limits; denials for medical necessity are subject to utilization review.

Prior authorizationAll claim submissions for these drugs remain subject to Blue Cross & Blue Shield of Rhode Island prior authorization requirements.

Benefit variabilityCoverage applicability may vary by group/contract; refer to the member’s Benefit Booklet, Evidence of Coverage, or Subscriber Agreement for specific benefit determinations.